Summary:
Infusion of dimethylsulfoxide (DMSO) contained in cryopreserved and thawed hematopoietic stem cell (HSC) grafts is frequently associated with mild or moderate adverse reactions, and occasionally with more severe events including neurological symptoms. The severity of these complications is related to the amount of residual DMSO. We evaluated a recently available, closed, automated and ‘cgmp (current good manufacturing practice) compliant’ device (CytoMateTM) for its ability to wash out DMSO at the expense of a limited loss of viable CD34+ cells. A total of 16 procedures were carried out with 39 blood HSC bags intended for destruction. Mean amounts of DMSO for each cellular product (one, two or three bags) were between 12.2 and 39.6 g before thawing; after the washing procedure, residual DMSO quantities were between 0.1 and 3.7 g. When set up to reproducibly allow for a more than 96% elimination of DMSO, processing of thawed cells with the CytoMateTM cell processor resulted in a mean recovery of viable total cells, CD34+ cells and lymphocyte subsets above 60%. We conclude that this simple and efficient washing technique is suitable for routine processing of HSC grafts. Clinical studies will demonstrate whether a reduction in the incidence of adverse effects associated with DMSO infusion is observed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zambelli A, Poggi G, Da Prada G et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 18: 4705–4708.
Okamoto Y, Takaue Y, Saito S et al. Toxicities associated with cryopreserved and thawed peripheral blood stem cell autografts in children with active cancer. Transfusion 1993; 33: 578–581.
Alessandrino P, Bernasconi P, Caldera D et al. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transplant 1999; 23: 533–537.
Lopez-Jimenez J, Cervero C, Munoz A et al. Cardiovascular toxicities related to the infusion of cryopreserved grafts: results of a controlled study. Bone Marrow Transplant 1994; 13: 789–973.
Perseghin P, Balduzzi A, Bonanomi S et al. Infusion-related side-effects in children undergoing autologous hematopoietic stem cell transplantation for acute leukemia. Bone Marrow Transplant 2000; 26: 116–118.
Davis JM, Rowley SD, Braine HG et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781–786.
Styler MJ, Topolsky DL, Crilley PA et al. Transient high grade heart block following autologous bone marrow infusion. Bone Marrow Transplant 1992; 10: 435–438.
Keung YK, Lau S, Elkayam U et al. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant 1994; 14: 363–367.
Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998–1004.
Dhodapkar M, Goldberg SL, Tefferi A et al. Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion. Am J Hematol 1994; 45: 187–188.
Hoyt R, Szer J, Grigg A . Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transplant 2000; 25: 1285–1287.
Rapoport AP, Rowe JM, Packman CH et al. Cardiac arrest after autologous marrow infusion. Bone Marrow Transplant 1991; 7: 401–403.
Bond GR, Curry SC, Dahl DW . Dimethylsulphoxide-induced encephalopathy. Lancet 1989; 1: 1134–1135.
Kessinger A, Armitage JO, Smith DM et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260–1265.
Shpall E, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy-coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high dose chemotherapy. Blood 1997; 90: 4313–4320.
Chabannon C, Cornetta K, Lotz JP et al. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicenter study. Br J Cancer 1998; 78: 913–921.
Yanovich S, Mitsky P, Cornetta K et al. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 2000; 25: 1165–1174.
Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779.
Ayello J, Hesdorffer C, Reiss RF . A semiautomated technique for volume reduction of stem cell suspensions for autotransplantation. J Hematother 1995; 4: 545–549.
Del Mastro L, Venturini M, Viscoli C et al. Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. Ann Oncol 2001; 12: 505–508.
Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995; 92: 10119–10122.
Beaujean F, Hartmann O, Kuentz M et al. A simple, efficient washing procedure for cryopreserved human hematopoietic stem cells prior to reinfusion. Bone Marrow Transplant 1991; 8: 291–294.
Olivero S, Alario T, Ladaique P et al. CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. Bone Marrow Transplant 1999; 23: 387–394.
Keeney M, Chin-Yee I, Weir K et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998; 34: 61–70.
Metcalf D . Techniques for the Clonal Culture of Hemopoietic Cells: Techniques and Applications. Elsevier: New York, 1984.
Houze P, Dal Cortivo L, Anselme M et al. Quantification of residual dimethyl sulfoxide in supernatants of haematopoietic stem cells by capillary zone electrophoresis. J Chromatogr B Biomed Sci Appl 1999; 728: 75–83.
Acknowledgements
This work was supported in part by Institut Paoli-Calmettes. We thank the technical staff of the Cell and Gene Therapy Facility (Centre de Thérapie Cellulaire et Génique) for the excellent laboratory expertise in the processing of grafts and in flow cytometry analyses. This work has been presented in part at the Eigth Annual Meeting of the International Society for Cell Therapy (ISCT).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Calmels, B., Houzé, P., Hengesse, JC. et al. Preclinical evaluation of an automated closed fluid management device: CytomateTM, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transplant 31, 823–828 (2003). https://doi.org/10.1038/sj.bmt.1703905
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703905
Keywords
This article is cited by
-
Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion
Bone Marrow Transplantation (2014)
-
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
Cancer Immunology, Immunotherapy (2014)
-
Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide
Cell and Tissue Banking (2012)